Profil
Robert C.
Seid has been Vice President of Formulations for Iomai Corp.
since August 2005.
Prior to joining Iomai, he was Senior Director of Formulations and Process Development for Wyeth Wyeth Research and Director of Formulation Development for Aviron, Inc. He had over 20 years of experience in directing formulation optimization and characterization of biological products.
Dr. Seid received a BS degree in Chemistry from the University of California, Berkeley and a PhD in Chemistry from Boston University.
Postes actifs de Robert C. Seid
| Sociétés | Poste | Début |
|---|---|---|
| IOMAI CORPORATION | Corporate Officer/Principal | 01/08/2008 |
Anciens postes connus de Robert C. Seid
| Sociétés | Poste | Fin |
|---|---|---|
MedImmune Vaccines, Inc.
MedImmune Vaccines, Inc. BiotechnologyHealth Technology Develops, manufactures and markets live vaccines | Corporate Officer/Principal | - |
Wyeth Research
Wyeth Research Miscellaneous Commercial ServicesCommercial Services Discovers and develops platforms encompassing pharmaceuticals | Corporate Officer/Principal | - |
Formation de Robert C. Seid
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
MedImmune Vaccines, Inc.
MedImmune Vaccines, Inc. BiotechnologyHealth Technology Develops, manufactures and markets live vaccines | Health Technology |
Boston University
Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Intercell USA, Inc.
Intercell USA, Inc. BiotechnologyHealth Technology Discovers and develops vaccines and immune system stimulants | Health Technology |
Wyeth Research
Wyeth Research Miscellaneous Commercial ServicesCommercial Services Discovers and develops platforms encompassing pharmaceuticals | Commercial Services |
















